Notice of Special Topics of Interest for CDER for PAR-23-072 "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)"
Notice Number:

Key Dates

Release Date:

February 6, 2023

Related Announcements


Issued by



This Notice is to notify applicants that the Center for Drug Evaluation and Research (CDER) is currently accepting applications to support the organization of public conferences under the Controlled Substances Program (CSP). 

CDER/CSP is interested in applications that propose one or more workshops to address topics including, but not limited to the following:

  • Adults with attention-deficit/hyperactivity disorder (ADHD): considerations for diagnosis and treatment
  • Root causes, perceptions, and consequences of non-medical use of prescription stimulants including overdosage and toxicity
  • Emerging substances with abuse potential 

For more information, please visit  

The FDA recognizes the value of supporting high quality conferences and scientific meetings relevant to its mission and to the public health. A conference or scientific meeting is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or virtually, to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge impacting the public's health within the scope of the FDA's mission, whether or not a published report results from such meeting. Support of such meetings is contingent upon the fiscal and programmatic interests and priorities of the FDA's respective Offices and Centers.


Please direct all inquiries to:

Janelle Fundersburg
Office of Acquisitions & Grants Services (OAGS)
Food and Drug Administration